84
Participants
Start Date
July 28, 2025
Primary Completion Date
March 31, 2028
Study Completion Date
October 31, 2028
OPN-375
OPN-375 (fluticasone propionate) delivered via exhalation delivery system (EDS) BID
Placebo
Placebo solution administered via exhalation delivery system (EDS).
NOT_YET_RECRUITING
University of Rochester Medical Center, Rochester
RECRUITING
Centers for Advanced ENT Care, Towson
NOT_YET_RECRUITING
EVMS at Old Dominion University, Norfolk
RECRUITING
Charleston ENT & Allergy, North Charleston
NOT_YET_RECRUITING
Children's Healthcare of Atlanta, Atlanta
RECRUITING
Kentuckiana ENT, Louisville
NOT_YET_RECRUITING
Southern Illinois University School of Medicine, Springfield
NOT_YET_RECRUITING
University of Missouri Medical Center, Columbia
RECRUITING
Allergy, Asthma and Clinical Research Center, Oklahoma City
RECRUITING
Vital Prospects Clinical Research Institute, Tulsa
RECRUITING
STAAMP Research, San Antonio
RECRUITING
Orion Clinical Research, Austin
NOT_YET_RECRUITING
Children's Hospital Colorado, Aurora
RECRUITING
Colorado ENT & Allergy, Colorado Springs
NOT_YET_RECRUITING
University of Utah, Salt Lake City
NOT_YET_RECRUITING
San Tan Allergy & Asthma, Gilbert
RECRUITING
Breathe Clear Institute, Torrance
NOT_YET_RECRUITING
Children's Hospital of Orange County, Orange
RECRUITING
DaVinci Research, LLC, Sacramento
Optinose US Inc.
INDUSTRY